Figures compiled for The Globe and Mail by IMS Health, an independent firm that tracks pharmaceutical sales, show prescriptions for Ritalin and other amphetamine-like drugs for Attention Deficit Hyperactivity Disorder shot up to 2.9 million in 2009, a jump of more than 55 per cent in four years.